MedTrace Logo

ACT-20 in Patients With Severe COVID-19 Pneumonia

NCT04398303 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2020-05-21

No results posted yet for this study

Summary

The primary objective of this study is determine the safety and efficacy of ACT-20-MSC (allogenic human umbilical derived mesenchymal stem cells) and ACT-20-CM (allogenic human umbilical derived mesenchymal stem cells in conditioned media) in patients with moderate to severe COVID-19 pneumonia.

Conditions

Interventions

BIOLOGICAL

ACT-20-MSC

1 million cells / kg body weight in 100 ml in conditioned media

BIOLOGICAL

ACT-20-CM

100 ml of conditioned media only

BIOLOGICAL

Placebo

100 ml of MEM-α

Sponsors & Collaborators

  • Aspire Health Science

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398303 on ClinicalTrials.gov